A Study of Balapiravir in Patients With Dengue Virus Infection
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, multiple-dose, placebo-controlled study will evaluate the
safety, tolerability and efficacy of balapiravir in adult male patients with confirmed dengue
virus infection whose symptoms began within the 48 hours preceding the first administration
of balapiravir. Patients will be randomized to receive either balapiravir or placebo, orally
twice daily for 5 days. Anticipated time on treatment as in-patient is 7 days, with an
out-patient follow-up to week 12. Target sample size is <200